Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

DaVita (DVA)

NYSE: DVA · Health Care Services · Denver, CO

Our rating: Positive

Positive reaffirmed at $187.50, moderate conviction, October 30, 2026.

Breaks if: The positive view breaks if reported free cash flow for FY2027 comes in below $1.0B — roughly 25% below the current $1.3B level — as that would signal that reimbursement pressure or rising operating costs are compressing the cash engine faster than top-line growth can offset, invalidating the core FCF-yield thesis. On price, if the stock cannot hold above $150 over the next twelve months without a recovery in FCF expectations, the valuation cushion that underpins the call has closed.

Key figures

Market value$10.1B
Revenue, last 12 months$14.2B
Net income, last 12 months$920M
Free cash flow, last 12 months$1.3B
Price to earnings11.0×
Free cash flow yield12.8%
Dividend yield0.0%
Operating margin15.0%
Return on equityn/a
Beta to the S&P 5000.32
Volatility, annualized38.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$3.6B4.6%$3.40$359M
June 30, 2026$3.6B5.2%$4.02$320M
March 31, 2026$3.4B6.0%$2.87$219M
December 31, 2025$3.6B9.9%$3.22$395M
September 30, 2025$3.4B4.8%$2.04$675M
June 30, 2025$3.4B6.1%$2.58$203M
March 31, 2025$3.2B5.0%$2.00$37M
December 31, 2024$3.3B4.7%$3.07$377M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

11 ledger entries and 48 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.